Nicklaus Brandehoff1, Axel Adams2, Kyle McDaniel3, Samuel D Banister4, Roy Gerona2, Andrew A Monte1,3. 1. a Rocky Mountain Poison & Drug Center, Denver Health and Hospital Authority , Denver , CO , USA. 2. b Clinical Toxicology and Environmental Biomonitoring Lab , University of California San Francisco , San Francisco , CA , USA. 3. c Department of Emergency Medicine , University of Colorado School of Medicine , Aurora , CO , USA. 4. d Medicinal Chemistry Knowledge Center , ChEM-H, Stanford University , Stanford, CA , USA.
Abstract
BACKGROUND: Use of new psychoactive substances (NPS) has increased over the last decade. During this period, variability of both clinical presentations and chemical compositions of these compounds has increased. Synthetic cannabinoids (SCs) are the most commonly used NPS and there are more than 100 documented unique molecules in this class. "Black Mamba", often associated to ADB-FUBINACA, is the most commonly used SC in Colorado. It has been linked to kidney injury, myocardial toxicity, seizures, and death. OBJECTIVES: We aim to identify the chemical constituents and quantification of eight cases of reported "Black Mamba" use in order to further understand the clinical variability in patients presenting for emergency stabilization. METHODS: We report data from eight cases of reported "Black Mamba" use prospectively captured through the Colorado site of the Psychoactive Surveilance Consortium and Analysis Network (P SCAN). P SCAN is a geographically representative group of academic hospitals that capture clinical presentation, outcome, and biologic samples from patients that present for emergency stabilization following NPS use. Serum and urine samples were analyzed and quantified by liquid chromatography-quadrupole time-of-flight mass spectrometry after a qualitative screen for over 600 unique NPS compounds. RESULTS: In the reported eight cases, the median age was 28 years old. There were four male and four females. Four patients had agitation/delirium and four patients had chest pain. Normal saline, benzodiazepines and ondansetron were the common treatment provided in the emergency department (ED). Two patients were discharged from the ED and six patients being admitted for emergency observation with a median length of stay (LOS) of six hours. No deaths were reported. Confirmatory testing revealed that only five patients (62.5%) had SCs found in blood or urine samples. Cocaine, NRG-3, 3-methoxyphencyclidine hydrochloride (MeO-PCP), and methamfetamine were identified in other presentations. CONCLUSIONS: The wide range of clinical presentations from "Black Mamba" use may be explained by the wide variability of chemical constituents found by laboratory analysis.
BACKGROUND: Use of new psychoactive substances (NPS) has increased over the last decade. During this period, variability of both clinical presentations and chemical compositions of these compounds has increased. Synthetic cannabinoids (SCs) are the most commonly used NPS and there are more than 100 documented unique molecules in this class. "Black Mamba", often associated to ADB-FUBINACA, is the most commonly used SC in Colorado. It has been linked to kidney injury, myocardial toxicity, seizures, and death. OBJECTIVES: We aim to identify the chemical constituents and quantification of eight cases of reported "Black Mamba" use in order to further understand the clinical variability in patients presenting for emergency stabilization. METHODS: We report data from eight cases of reported "Black Mamba" use prospectively captured through the Colorado site of the Psychoactive Surveilance Consortium and Analysis Network (P SCAN). P SCAN is a geographically representative group of academic hospitals that capture clinical presentation, outcome, and biologic samples from patients that present for emergency stabilization following NPS use. Serum and urine samples were analyzed and quantified by liquid chromatography-quadrupole time-of-flight mass spectrometry after a qualitative screen for over 600 unique NPS compounds. RESULTS: In the reported eight cases, the median age was 28 years old. There were four male and four females. Four patients had agitation/delirium and four patients had chest pain. Normal saline, benzodiazepines and ondansetron were the common treatment provided in the emergency department (ED). Two patients were discharged from the ED and six patients being admitted for emergency observation with a median length of stay (LOS) of six hours. No deaths were reported. Confirmatory testing revealed that only five patients (62.5%) had SCs found in blood or urine samples. Cocaine, NRG-3, 3-methoxyphencyclidine hydrochloride (MeO-PCP), and methamfetamine were identified in other presentations. CONCLUSIONS: The wide range of clinical presentations from "Black Mamba" use may be explained by the wide variability of chemical constituents found by laboratory analysis.
Entities:
Keywords:
Black Mamba; novel psychoactive substances; public health; synthetic cannabinoid
Authors: Andrew A Monte; Alvin C Bronstein; Dazhe J Cao; Kennon J Heard; Jason A Hoppe; Christopher O Hoyte; Janetta L Iwanicki; Eric J Lavonas Journal: N Engl J Med Date: 2014-01-23 Impact factor: 91.245
Authors: Axel J Adams; Samuel D Banister; Lisandro Irizarry; Jordan Trecki; Michael Schwartz; Roy Gerona Journal: N Engl J Med Date: 2016-12-14 Impact factor: 91.245
Authors: Samuel D Banister; Mitchell Longworth; Richard Kevin; Shivani Sachdev; Marina Santiago; Jordyn Stuart; James B C Mack; Michelle Glass; Iain S McGregor; Mark Connor; Michael Kassiou Journal: ACS Chem Neurosci Date: 2016-07-27 Impact factor: 4.418
Authors: Christopher O Hoyte; Jeena Jacob; Andrew A Monte; Mohammed Al-Jumaan; Alvin C Bronstein; Kennon J Heard Journal: Ann Emerg Med Date: 2012-05-09 Impact factor: 5.721
Authors: Andrew A Monte; Andrew Hopkinson; Jessica Saben; Shelby K Shelton; Stephen Thornton; Aaron Schneir; Adam Pomerleau; Robert G Hendrickson; Ann M Arens; Jon B Cole; James Chenoweth; Spencer Martin; Axel Adams; Samuel D Banister; Roy R Gerona Journal: Addiction Date: 2019-11-25 Impact factor: 6.526
Authors: Catheryn D Wilson; Sherrica Tai; Laura Ewing; Jasmine Crane; Taylor Lockhart; Ryochi Fujiwara; Anna Radominska-Pandya; William E Fantegrossi Journal: J Pharmacol Exp Ther Date: 2018-11-12 Impact factor: 4.030
Authors: Michal Ordak; Aleksandra Zmysłowska; Miłosz Bielski; Daniel Rybak; Maja Tomaszewska; Katarzyna Wyszomierska; Aleksandra Kmiec; Natalia Garlicka; Maria Zalewska; Michal Zalewski; Tadeusz Nasierowski; Elzbieta Muszynska; Magdalena Bujalska-Zadrozny Journal: Front Psychiatry Date: 2021-04-23 Impact factor: 4.157
Authors: Eric Sparkes; Rochelle Boyd; Shuli Chen; Jack W Markham; Jia Lin Luo; Tahira Foyzun; Humayra Zaman; Charlotte Fletcher; Ross Ellison; Iain S McGregor; Marina J Santiago; Felcia Lai; Roy R Gerona; Mark Connor; David E Hibbs; Elizabeth A Cairns; Michelle Glass; Adam Ametovski; Samuel D Banister Journal: Front Psychiatry Date: 2022-09-28 Impact factor: 5.435